Bristol-Myers Squibb Company
430 E. 29th St
14th Floor
New York
New York
10016
United States
Tel: 212-546-4000
Fax: 212-546-4020
Website: http://www.bms.com/
About Bristol-Myers Squibb Company
Bristol-Myers Squibb is a global biopharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
2048 articles with Bristol-Myers Squibb Company
-
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
-
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
-
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
-
Celgene, which will become part of Bristol-Myers Squibb later this year, saw positive growth in the first quarter of the year.
-
One of the criticisms of the biopharma industry—at least in the context of drug pricing—is how much the industry as a whole spends on lobbyists. For example, last year, PhRMA, the industry lobbying group, spent more than $27.5 million on its lobbying activities.
-
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
4/17/2019
Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) (“Celgene”), of an exchange offer for any and all outstanding notes (the “Celgene Notes”) issued by Celgene for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb (the “Bristol-Myers Squibb Notes”) and cash.
-
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
-
Celgene Stockholders Approve Proposed Acquisition by Bristol-Myers Squibb
4/12/2019
Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (NYSE: BMY).
-
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
4/12/2019
Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG) at the Special Meeting of Stockholders.
-
The combination of Opdivo and Yervoy actually fared worse than placebo, according to the data presented at the conference.
-
Bristol-Myers Squibb released data from pooled analyses of survival data from four clinical studies in patients with lung cancer treated with Opdivo (nivolumab).
-
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
4/2/2019
Bristol-Myers Squibb Company (NYSE: BMY) today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four studies, 14% of all Opdivo-treated patients were alive at four years
-
Starboard Value Backs Down From BMS/Celgene Fight After Proxy Advisory Firms Announce Support
4/1/2019
Shares of Bristol-Myers Squibb are up slightly this morning after the proposed $74 billion acquisition of Celgene gained some significant support over the weekend. That support has caused at least one opposition group to withdraw from the fight. -
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
3/29/2019
Bristol-Myers Squibb Company (NYSE:BMY) today announced that independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), recommend that Bristol-Myers Squibb shareholders vote “FOR” the approval of the issuance of shares of Bristol-Myers Squibb common stock in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG).
-
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
3/29/2019
Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC (collectively, "Alvogen") relating to patents for Revlimid
-
Supporters and those opposed to the proposal are marshaling their forces ahead of the April 12 shareholder vote.
-
BMS inked a multi-year strategic agreement with Concerto HealthAI, which focuses on oncology-specific Real-World Data (RWD) and advanced AI for Real-World Evidence (RWE) generation.
-
Today, Celgene submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its ozanimod for adults with relapsing forms of multiple sclerosis (RMS).
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials
3/25/2019
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card